Drugs / TROP2-CAR-NK Cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06358430 | Dec 2024 → Jan 2029 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06066424 | Oct 2023 → Apr 2038 expected | cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TROP2-CAR-NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06066424 ↗ |
| Modality | Cell therapy | “TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells” NCT06066424 ↗ |
| Route | Intravenous | “Given by (IV) vein” NCT06066424 ↗ |